Saturday, November 27, 2021 4:03:03 PM
In January of 2020 the world saw the emergence of the COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared COVID-19 a global health emergency in January of 2020. Within three months of initial discovery COVID-19 was declared a global pandemic, reflecting alarming levels of spread and severity and resulting in unprecedented action by local and national governments to restrict the movement of citizens to contain the spread. Building immunity to the disease is the key to stopping its spread. A COVID-19 vaccine would train the immune system to recognize and destroy the virus without the vaccinated person getting sick.
Coronaviruses mostly infect animals, including birds and mammals. In humans, they mostly cause mild respiratory infections. However, some recent human coronavirus infections have resulted in lethal endemics, which include the Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) endemics. Reported studies suggest that SARS-CoV-2 is similar to SARS-CoV based on analysis of the full-length genome. Various studies of SARS-CoV infection suggest a protective role of both antibody and T-cell immune responses. Multiple reports suggest that antibodies generated against SARS-CoV, were highly prevalent in SARS-CoV-infected patients. Although effective, the antibody response was determined to be short-lived in convalescent SARS-CoV patients. In contrast, T-cell responses have been shown to provide long-term protection more than ten years after infection. PDS Biotech is utilizing the unique immunological properties of Versamune® to develop a transformative vaccine that induces both antibodies and T-cells against the virus.
PDS0203 is currently in pre-clinical development.
Recent PDSB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 09:33:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 09:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 10:10:16 PM
- PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer • GlobeNewswire Inc. • 01/22/2024 09:45:19 PM
- PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/04/2023 09:50:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 09:02:38 PM
- PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer • GlobeNewswire Inc. • 11/28/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 11:02:46 AM
- PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/14/2023 12:30:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:07:59 PM
- PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/07/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 08:06:44 PM
- PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO • GlobeNewswire Inc. • 10/23/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 08:02:24 PM
- PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer • GlobeNewswire Inc. • 10/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:03:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:03:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 01:02:10 PM
- PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) • GlobeNewswire Inc. • 10/03/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 08:05:34 PM
- PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA) • GlobeNewswire Inc. • 10/02/2023 12:00:00 PM
- PDS Biotech to Present at the LD Micro Main Event XVI • GlobeNewswire Inc. • 09/26/2023 12:00:00 PM
- PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 • GlobeNewswire Inc. • 09/25/2023 12:00:13 PM
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM